MIDATECH PHARMA ESPANA SL

Their core work

Midatech Pharma España is a Spanish biotech SME specializing in gold nanoparticle-based drug delivery systems, with a strong focus on glyco-nanoparticles and carbohydrate-functionalized nanostructures for pharmaceutical applications. They develop scalable manufacturing processes to bring nanoparticle therapies from lab to clinical production. Their work sits at the intersection of nanotechnology and immunology, particularly in designing carbohydrate-based immunomodulators that target specific immune receptors for therapeutic purposes.

What they specialise in

How they've shifted over time

Midatech Pharma España began its H2020 activity (2015) with a dual focus: manufacturing scale-up for nanoparticles (NANOFACTURING) and carbohydrate-based immune targeting (IMMUNOSHAPE). By 2018, their work shifted more explicitly toward glyco-nanoparticle design and understanding bionano interactions, as seen in the NanoCarb project with its emphasis on sugars, glycans, and corona behavior. The trajectory suggests a move from production engineering toward more fundamental nanomedicine design, particularly in how carbohydrate coatings influence nanoparticle behavior in the body.

Moving from manufacturing process development toward designing biologically active nanoparticle surfaces, suggesting future work will combine their production capabilities with advanced carbohydrate-based targeting.

How they like to work

With 1 coordination and 2 participations across 3 projects, Midatech Pharma España operates as both a project leader and a contributing partner, though their largest investment by far was in the coordinator role (NANOFACTURING at EUR 2.5M vs under EUR 250K as participant). They have worked with 36 unique partners across 12 countries, indicating a broad European network for a 3-project SME. This breadth suggests they are well-connected in the nanomedicine community and comfortable operating in large, multinational consortia.

Despite only 3 projects, Midatech Pharma España has built a network of 36 partners across 12 countries, reflecting participation in sizable consortia typical of MSCA training networks and RIA projects. Their network spans a wide European footprint relative to their project count.

What sets them apart

Midatech Pharma España combines two capabilities rarely found together in a single SME: hands-on experience scaling nanoparticle manufacturing to clinical-grade production AND deep knowledge of carbohydrate surface chemistry for biological targeting. For consortium builders, this means a partner who can both design functionally coated nanoparticles and contribute manufacturing know-how to move them toward real-world application. Their location in the Basque Country's Derio biotech hub also connects them to Spain's growing nanomedicine ecosystem.

Highlights from their portfolio

• NANOFACTURING
  Their largest project (EUR 2.5M) and only coordination — tackling the critical bottleneck of scaling nanoparticle production from lab bench to sustainable manufacturing platforms.
• NanoCarb
  A 5-year MSCA training network on glyco-nanoparticles in advanced nanomedicine, signaling Midatech's commitment to building the next generation of researchers in their core domain.